Occurrence of additional GTF2I-fusions; GTF2I-BRAF 4–10 (primary melanoma) [29], GTF2I-NCOA2 (soft tissue angiofibroma development) [34] and GTF2I-RARA (acute promyelocytic leukemia) [35], further supports a oncogenic role. Here, RARA is linked to acute promyelocytic leukemia.